B. Ojeda

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Luca Gianni, W. Eiermann, Alexey Manikhas et al. · The Lancet · 2010 · 1.3K citations

Medicine, Oncology, Breast Oncology +16

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

Luca Gianni, W. Eiermann, Aňa Lluch et al. · The Lancet Oncology · 2014 · 491 citations

Medicine, Oncology, Breast Oncology +16

Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas

Alberto Gallardo, Enrique Lerma, Daniel Escuín et al. · British Journal of Cancer · 2012 · 231 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.

Rámón Colomer, Sagrario Montero, Aňa Lluch et al. · PubMed · 2000 · 172 citations

Medicine, Oncology, Pharmacology +17

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer

José Baselga, J. G. M. Segalla, Henri Roché et al. · Journal of Clinical Oncology · 2012 · 163 citations · Full text

Medicine, Oncology, Pharmacology +15